Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Is Expanded Mutation Testing Practical for CF Carrier Screening?

By LabMedica International staff writers
Posted on 06 Dec 2010
A new study questioned the value of expanded genetic testing for cystic fibrosis.

The findings suggested that expanded panels might promote ill-informed decisions and anxiety for physicians and couples seeking testing to determine their risk of passing the disease to their children.

Testing for genetic mutations beyond those medically recommended is unlikely to prevent the birth of children with classic cystic fibrosis and may detect mutations causing only mild disease, according to an eight-year study performed by scientists at Quest Diagnostics (Madison, NJ, USA). More...


Participants in the study came from an ethnically diverse American population. It involved analyses of more than three million deidentified test results performed by the company's laboratories over an eight-year period ending in April 2010.

The company's scientists found that CF testing, using 23 recommended mutations plus an additional eight to nine clinically validated mutations performed for patients in its labs, identified nearly 100 % of carriers among Caucasians, including Ashkenazi Jews, the highest risk group for CF, as compared to well-established estimated carrier rates. The CF testing also performed comparably to the American College of Obstetricians and Gynecologists (ACOG; Washington DC, USA) predictions for performance in detecting carriers in African, Hispanic, and Asian Americans.

In 2004, the American College of Medical Genetics (ACMG; Bethesda, MD, USA) and ACOG recommended physicians offer panels based on the 23 recommended mutations to couples to help identify carrier status. Despite the guidelines, expanded test panels that identify dozens up to nearly 100 nonguideline recommended mutations are widely offered by certain laboratories in the US.

The study findings appear online in the journal Genetics in Medicine.

"This outstanding study should finally put to rest the continuing debates and misinformation that suggest more mutations are always better when it comes to cystic fibrosis carrier screening," said Wayne W. Grody, MD, PhD, professor in the departments of pathology and laboratory medicine, pediatrics, and Human Genetics at the UCLA School of Medicine (Los Angeles, CA, USA). Dr. Grody led one of the influential NIH-funded pilot studies on CF carrier screening and cochaired the ACMG committee that developed the recommended core mutation-screening panel. He is not affiliated with the study or with Quest Diagnostics.

Related Links:
Quest Diagnostics
American College of Obstetricians and Gynecologists
American College of Medical Genetics
UCLA School of Medicine


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.